Nieuws en video's - COMPUGEN

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 PR Newswire HOLON, Israel, April 10, 2024 HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the simultaneous online publication of a peer reviewed paper titled 'Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent...

Compugen to Participate in Two Upcoming Investor Conferences PR Newswire HOLON, Israel, April 3, 2024 HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming investor conferences in April: 23 rd Annual Needham Virtual Healthcare Conference Date: Wednesday, April 10, 2024 , at 8:00 AM ET Location:...

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy PR Newswire HOLON, Israel, March 11, 2024 HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming...

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 PR Newswire HOLON, Israel, March 6, 2024 HOLON, Israel , March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer...

Compugen Reports Fourth Quarter and Full Year 2023 Results PR Newswire HOLON, Israel, March 5, 2024 Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple data readouts and updates planned from Compugen's diversified portfolio Solid balance sheet with extended cash runway expected to fund operations into 2027 HOLON, Israel , March 5, 2024 /PRNewswire/ --...

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 PR Newswire HOLON, Israel, Feb. 26, 2024 HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida , on Monday, March 11, 2024 at 11:20 AM ET . A live...

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024 PR Newswire HOLON, Israel, Feb. 20. 2024 HOLON, Israel , Feb. 20 . 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024 , before the U.S. financial markets open. Management will...

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer PR Newswire HOLON, Israel, Feb. 15, 2024 HOLON, Israel , Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) , a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler , M.D., as Chief Medical Officer, effective March 1, 2024 . Michelle will succeed Henry Adewoye , M.D., who is leaving Compugen to pursue other...

Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire HOLON, Israel, Jan. 8, 2024 HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN),...

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire HOLON, Israel, Jan. 8, 2024 HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024 , it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the...

Thinking about buying stock in Compugen, Hanryu Holdings, Super Micro Computer, Coterra Energy, or Applied Therapeutics? PR Newswire NEW YORK, Dec. 19, 2023 NEW YORK , Dec. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGEN, HRYU, SMCI, CTRA, and APLT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CGEN:...

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire HOLON, Israel, Dec. 19, 2023 Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a...

Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology PR Newswire HOLON, Israel, Dec. 19, 2023 Conference call today, December 19, 2023 , 8:30 AM ET to discuss the license agreement HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it...

Compugen Reports Third Quarter 2023 Results PR Newswire HOLON, Israel, Nov. 7, 2023 Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in combination with chemotherapy Clinical data presented at SITC 2023 reinforces COM701 (anti-PVRIG) mediated anti-tumor activity in tumors typically not responding to immunotherapy and initial data suggest PVRL2 as a...

Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy PR Newswire HOLON, Israel, Nov. 6, 2023 COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations mediated clinical benefit in platinum resistant ovarian cancer patients, independent of baseline inflammatory status and was associated with an...

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire HOLON, Israel, Nov. 3, 2023 HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on November 3, 2023 , it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its ordinary shares...

Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer PR Newswire HOLON, Israel, Oct. 31, 2023 COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor site expected to have a favorable therapeutic window compared to engineered cytokines Data to be presented in an oral...

Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023 PR Newswire HOLON, Israel, Oct. 24, 2023 HOLON, Israel , Oct. 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023 , before the U.S. financial markets open. Management will host a conference call...

Compugen to Present at Single Cell Genomics 2023 Meeting PR Newswire HOLON, Israel, Oct. 3, 2023 HOLON, Israel , Oct. 3, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023 , Engelberg,...

Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer PR Newswire HOLON, Israel, Oct. 2, 2023 HOLON, Israel , Oct. 2 , 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with a triple...